Telix Pharmaceuticals Ltd ADR TLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Telix Reports Third Quarter 2026 Financial Performance
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
Trading Information
- Previous Close Price
- $8.86
- Day Range
- $8.91–9.05
- 52-Week Range
- $6.29–13.09
- Bid/Ask
- $8.98 / $9.00
- Shares Outstanding
- 339.78M
- Market Cap
- $3.04B
- Volume/Avg
- 205,670 / 346,000
Key Statistics
- Price/Earnings (Normalized)
- 77.86
- Price/Sales
- 3.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,184
- Website
- https://www.telixpharma.com
Competitors
Valuation
Metric | TLX | VRTX | REGN |
|---|---|---|---|
Price/Earnings (Normalized) | 77.86 | 29.42 | 18.84 |
Price/Book Value | 8.20 | 6.48 | 2.96 |
Price/Sales | 3.26 | 10.55 | 6.05 |
Price/Cash Flow | — | 29.35 | 17.48 |
Price/Earnings
TLX
VRTX
REGN
Financial Strength
Metric | TLX | VRTX | REGN |
|---|---|---|---|
Quick Ratio | 1.74 | 1.72 | 2.72 |
Current Ratio | 2.01 | 2.34 | 3.35 |
Interest Coverage | 1.56 | 94.80 | 106.89 |
Quick Ratio
TLX
VRTX
REGN
Profitability
Metric | TLX | VRTX | REGN |
|---|---|---|---|
Return on Assets (Normalized) | 2.08% | 17.70% | 14.40% |
Return on Equity (Normalized) | 6.42% | 25.16% | 18.83% |
Return on Invested Capital (Normalized) | 5.73% | 20.26% | 15.64% |
Return on Assets
TLX
VRTX
REGN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|CFD?R>b | LOCK|kKr^Y | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!F$dJtN | LOCK|>%ldj | $99B | |||
| Moderna Inc MRNA | LOCK|@Ct^$@^ | LOCK|ln | $84B | |||
| argenx SE ADR ARGX | LOCK|#&<YzL | LOCK|h#d | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|MF>%t%^ | LOCK|$#N | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Z>#F>RjK | LOCK|^q!PD | $31B | |||
| Incyte Corp INCY | LOCK|dCfc%^K | LOCK|Cl# | $24B | |||
| BioNTech SE ADR BNTX | LOCK|yfP!pk# | LOCK|>q | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^Pnv!< | LOCK|pntF& | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|pzG!!b | LOCK|d! | $15B |